The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Keryx Biopharmaceuticals Inc

Nasdaq: KERX
Last

(U.S.) $4.47

Today's change-0.09 -1.97%
Updated December 12 4:00 PM -5GMT. Delayed by at least 15 minutes.
 

Keryx Biopharmaceuticals Inc

Nasdaq: KERX
Last

(U.S.) $4.47

Today's change-0.09 -1.97%
Updated December 12 4:00 PM -5GMT. Delayed by at least 15 minutes.

Keryx Biopharmaceuticals Inc down (U.S.)$0.09

Keryx Biopharmaceuticals Inc closed sharply lower Tuesday, dropping (U.S.)$0.09 or 1.97% to (U.S.)$4.47. Over the last five days, shares have lost 2.40% and sit 3.23% above their 52-week low. This security has underperformed the S&P 500 by 40.17% during the last year.

Key company metrics

  • Open(U.S.) $4.57
  • Previous close(U.S.) $4.56
  • High(U.S.) $4.59
  • Low(U.S.) $4.38
  • Bid / Ask(U.S.) $4.28 / (U.S.) $4.95
  • YTD % change-23.72%
  • Volume1,560,681
  • Average volume (10-day)1,759,871
  • Average volume (1-month)2,348,975
  • Average volume (3-month)1,643,632
  • 52-week range(U.S.) $4.33 to (U.S.) $8.38
  • Beta4.98
  • Trailing P/ENegative, not meaningful
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) -$1.50
Updated December 12 4:00 PM -5GMT. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
-323.92%

Although this company's net profit margin is negative, it is above the industry average and implies that Keryx Biopharmaceuticals Inc is operating more effectively than other companies in the industry.
Company Books

S&P TSX0.07%Sector:HealthcareIndustry:Biotechnology
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q3/2017Q2/2017Q1/2017Q4/2016
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedSep 30, 201709/30/2017Jun 30, 201706/30/2017Mar 31, 201703/31/2017Dec 31, 201612/31/2016
Revenue15151210
Total other revenue--------
Total revenue15151210
Gross profit8107-5
Total cost of revenue75514
Total operating expense39393543
Selling / general / administrative23252323
Research & development9976
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)--------
Other operating expenses, total--------
Operating income-24-24-23-34
Interest income (expense), net non-operating--------
Gain (loss) on sale of assets--------
Other--------
Income before tax-23-86-23-34
Income after tax-23-86-23-34
Income tax, total0000
Net income-23-86-23-34
Total adjustments to net income--------
Net income before extra. items-23-86-23-34
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items-23-86-23-34
Inc. avail. to common incl. extra. items-23-86-23-34
Diluted net income-23-86-23-34
Dilution adjustment------0
Diluted weighted average shares119113107106
Diluted EPS excluding extraordinary itemsvalue per share-0.20-0.77-0.21-0.32
Dividends per sharevalue per share0.000.000.00--
Diluted normalized EPSvalue per share-0.20-0.77-0.21-0.32